Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC).
作者信息
Yan Yihe, Zheng Leting, Du Qiang, Geller David A
出版信息
Oncotarget. 2021 Nov 9;12(23):2316-2317. doi: 10.18632/oncotarget.27995.
Abstract
摘要
相似文献
1
Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC).γ干扰素/干扰素调节因子-1通路对肝细胞癌（HCC）中程序性死亡受体配体1（PD-L1）表达的调控机制及其与免疫检查点阻断的相关性
Oncotarget. 2021 Nov 9;12(23):2316-2317. doi: 10.18632/oncotarget.27995.
2
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.SIRT7 缺失通过 MEF2D 调控程序性细胞死亡配体 1 增加肝癌细胞中检查点抑制剂的疗效。
Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31.
3
Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma.长链非编码核糖核酸X染色体失活特异性转录本在肝细胞癌中通过miR-194-5p和miR-155-5p的共享途径调控免疫检查点程序性死亡配体1中的关键作用
World J Hepatol. 2020 Dec 27;12(12):1211-1227. doi: 10.4254/wjh.v12.i12.1211.
4
Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.联合抑制转化生长因子-β1诱导的上皮-间质转化和程序性死亡配体1沉默可使肝细胞癌对索拉非尼治疗重新敏感。
J Clin Med. 2021 Apr 27;10(9):1889. doi: 10.3390/jcm10091889.
5
Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.肿瘤周围单核细胞的糖酵解激活通过 PFKFB3-PD-L1 轴促进人肝癌中的免疫特权。
J Hepatol. 2019 Aug;71(2):333-343. doi: 10.1016/j.jhep.2019.04.007. Epub 2019 May 7.
6
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.EZH2 负向调控肝细胞癌中 PD-L1 的表达。
J Immunother Cancer. 2019 Nov 14;7(1):300. doi: 10.1186/s40425-019-0784-9.
7
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.骨桥蛋白诱导集落刺激因子 1 信号破坏肿瘤相关巨噬细胞的迁移，使肝细胞癌对抗 PD-L1 阻断敏感。
Gut. 2019 Sep;68(9):1653-1666. doi: 10.1136/gutjnl-2019-318419. Epub 2019 Mar 22.
8
Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.抗 PD-1/PD-L1 阻断免疫疗法治疗乙型肝炎病毒感染相关的晚期肝细胞癌：文献综述。
Front Immunol. 2020 May 28;11:1037. doi: 10.3389/fimmu.2020.01037. eCollection 2020.
9
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells.MYC 抑制可增加干扰素 γ诱导的肝癌细胞中 PD-L1 的表达。
Mol Immunol. 2018 Sep;101:203-209. doi: 10.1016/j.molimm.2018.07.006. Epub 2018 Jul 5.
10
IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.白细胞介素-6和程序性死亡配体-1阻断联合治疗可抑制小鼠模型中肝细胞癌的发展。
Biochem Biophys Res Commun. 2017 Apr 29;486(2):239-244. doi: 10.1016/j.bbrc.2017.02.128. Epub 2017 Mar 1.
引用本文的文献
1
Roles of Interferon Regulatory Factor 1 in Tumor Progression and Regression: Two Sides of a Coin.干扰素调节因子 1 在肿瘤进展和消退中的作用：一枚硬币的两面。
Int J Mol Sci. 2024 Feb 10;25(4):2153. doi: 10.3390/ijms25042153.
2
Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma.靶向间变性淋巴瘤激酶可避免核糖核酸酶1诱导的免疫抑制并增强肝细胞癌的抗肿瘤免疫力。
Nat Commun. 2024 Feb 2;15(1):1009. doi: 10.1038/s41467-024-45215-0.
3
Expression of programmed death-ligand 1, IRF1 and CD8 T lymphocyte infiltration in a primary subset of breast cancer patients in Sudan.苏丹原发性乳腺癌患者中程序性死亡配体1、IRF1的表达及CD8 T淋巴细胞浸润情况
J Taibah Univ Med Sci. 2023 Sep 7;19(1):99-105. doi: 10.1016/j.jtumed.2023.08.006. eCollection 2024 Feb.
4
A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma.一种单核苷酸混合物增强分子靶向药物对肝细胞癌的抗肿瘤活性。
Front Pharmacol. 2022 Jun 27;13:951831. doi: 10.3389/fphar.2022.951831. eCollection 2022.
本文引用的文献
1
Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC).干扰素调节因子 1（IRF-1）通过 CXCL10/CXCR3 轴在肝细胞癌（HCC）中激活抗肿瘤免疫。
Cancer Lett. 2021 May 28;506:95-106. doi: 10.1016/j.canlet.2021.03.002. Epub 2021 Mar 6.
2
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
3
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.干扰素调节因子 1（IRF-1）和 IRF-2 调节肝癌（HCC）细胞中 PD-L1 的表达。
Cancer Immunol Immunother. 2020 Sep;69(9):1891-1903. doi: 10.1007/s00262-020-02586-9. Epub 2020 May 6.
4
Tumor Immunology and Tumor Evolution: Intertwined Histories.肿瘤免疫学和肿瘤进化：交织的历史。
Immunity. 2020 Jan 14;52(1):55-81. doi: 10.1016/j.immuni.2019.12.018.
5
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.泛肿瘤基因组生物标志物用于基于 PD-1 检查点阻断的免疫治疗。
Science. 2018 Oct 12;362(6411). doi: 10.1126/science.aar3593.
6
Regulation and Function of the PD-L1 Checkpoint.PD-L1 检查点的调控与功能
Immunity. 2018 Mar 20;48(3):434-452. doi: 10.1016/j.immuni.2018.03.014.
7
The immunology of hepatocellular carcinoma.肝细胞癌的免疫学。
Nat Immunol. 2018 Mar;19(3):222-232. doi: 10.1038/s41590-018-0044-z. Epub 2018 Jan 29.
8
Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.核 IRF-1 表达作为评估转移性黑色素瘤中 PD-L1 表达“能力”和对 PD-1 治疗反应的一种机制。
J Immunother Cancer. 2017 Mar 21;5:25. doi: 10.1186/s40425-017-0229-2. eCollection 2017.
9
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.癌症免疫疗法的原发性、适应性和获得性耐药性。
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
10
Programmed death ligand 1 expression in hepatocellular carcinoma: A prognostic marker and therapeutic target for liver cancer?
Hepatology. 2016 Dec;64(6):1847-1849. doi: 10.1002/hep.28803. Epub 2016 Oct 6.
Zotero 插件